Secondary histiocytic sarcoma with BRAF<sup>V600E</sup> mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapy.

Venkataraman, Vinayak; Massoth, Lucas R; Sullivan, Ryan J; Friedmann, Alison M

Secondary histiocytic sarcoma with BRAF^V600E mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapy.

Venkataraman, Vinayak; Massoth, Lucas R; Sullivan, Ryan J; Friedmann, Alison M.

Affiliation

Venkataraman V; Departments of Medicine and Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.
Massoth LR; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Sullivan RJ; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Friedmann AM; Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.

Pediatr Blood Cancer ; 68(10): e29166, 2021 10.

Article in En | MEDLINE | ID: mdl-34061432

Subject(s)

Histiocytic Sarcoma; Sarcoma; Histiocytic Sarcoma/drug therapy; Histiocytic Sarcoma/genetics; Humans; Mutation; Proto-Oncogene Proteins B-raf/genetics; TOR Serine-Threonine Kinases/genetics

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sarcoma / Histiocytic Sarcoma Limits: Humans Language: En Journal: Pediatr Blood Cancer Journal subject: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Year: 2021 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google